Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin

Bela Szende, Karoly Lapis, Tommie W. Redding, Gordan Srkalovic, Andrew V Schally

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

BDF female mice inoculated with MXT mammary adenocarcinoma were treated for 30 days with microcapsules of the luteinizing hormone-releasing hormone (LH-RH) agonist D-Trp-6-LH-RH (releasing 25 μg/day for 30 days), microcapsules of the somatostatin agonist RC-160 (liberating 25 μg/day for one month), or the combination of these peptides. Bilateral surgical ovariectomy was performed in one group which served as an additional control. Tumor volume was measured weekly during the treatment period of 30 days. When tumor volume changes in the treated groups were compared to the corresponding changes in controls, the combination of D-Trp-6-LH-RH and RC-160 was the most effective in inhibiting tumor growth and approached the effect of surgical ovariectomy. At the conclusion of the experiment, tumor weights were also measured. All peptide analogs inhibited tumor weight by 42 to 63%. In the D-Trp-6-LH-RH treated group, ovarian weights and uterine weights decreased by 48% and 52%, respectively, as compared to controls. Histologically, the regressive changes in tumors caused by the treatment with RC-160, D-Trp-6-LH-RH and their combination were characterized by the coexistence of apoptosis (programmed cell death) and coagulation necrosis. The transition of apoptosis into coagulation necrosis was a common finding. The term 'apoptotic index' is proposed for the ratio of tumorous glands containing apoptotic cells. The apoptotic index was higher in the treated groups than in the control.

Original languageEnglish
Pages (from-to)307-314
Number of pages8
JournalBreast Cancer Research and Treatment
Volume14
Issue number3
DOIs
StatePublished - Dec 1 1989
Externally publishedYes

Fingerprint

Somatostatin
Gonadotropin-Releasing Hormone
Tumor Burden
Cell Death
Apoptosis
Breast Neoplasms
Growth
Ovariectomy
Capsules
Necrosis
Weights and Measures
Peptides
Neoplasms
Adenocarcinoma
Breast
Control Groups
vapreotide

Keywords

  • apoptosis
  • D-Trp-6-LH-RH
  • luteinizing hormone-releasing hormone (LH-RH)
  • MXT mammary tumor
  • programmed cell death
  • somatostatin analog RC-160

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin. / Szende, Bela; Lapis, Karoly; Redding, Tommie W.; Srkalovic, Gordan; Schally, Andrew V.

In: Breast Cancer Research and Treatment, Vol. 14, No. 3, 01.12.1989, p. 307-314.

Research output: Contribution to journalArticle

@article{fbcf5d399a5945b182988d145d2eb620,
title = "Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin",
abstract = "BDF female mice inoculated with MXT mammary adenocarcinoma were treated for 30 days with microcapsules of the luteinizing hormone-releasing hormone (LH-RH) agonist D-Trp-6-LH-RH (releasing 25 μg/day for 30 days), microcapsules of the somatostatin agonist RC-160 (liberating 25 μg/day for one month), or the combination of these peptides. Bilateral surgical ovariectomy was performed in one group which served as an additional control. Tumor volume was measured weekly during the treatment period of 30 days. When tumor volume changes in the treated groups were compared to the corresponding changes in controls, the combination of D-Trp-6-LH-RH and RC-160 was the most effective in inhibiting tumor growth and approached the effect of surgical ovariectomy. At the conclusion of the experiment, tumor weights were also measured. All peptide analogs inhibited tumor weight by 42 to 63{\%}. In the D-Trp-6-LH-RH treated group, ovarian weights and uterine weights decreased by 48{\%} and 52{\%}, respectively, as compared to controls. Histologically, the regressive changes in tumors caused by the treatment with RC-160, D-Trp-6-LH-RH and their combination were characterized by the coexistence of apoptosis (programmed cell death) and coagulation necrosis. The transition of apoptosis into coagulation necrosis was a common finding. The term 'apoptotic index' is proposed for the ratio of tumorous glands containing apoptotic cells. The apoptotic index was higher in the treated groups than in the control.",
keywords = "apoptosis, D-Trp-6-LH-RH, luteinizing hormone-releasing hormone (LH-RH), MXT mammary tumor, programmed cell death, somatostatin analog RC-160",
author = "Bela Szende and Karoly Lapis and Redding, {Tommie W.} and Gordan Srkalovic and Schally, {Andrew V}",
year = "1989",
month = "12",
day = "1",
doi = "10.1007/BF01806302",
language = "English",
volume = "14",
pages = "307--314",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin

AU - Szende, Bela

AU - Lapis, Karoly

AU - Redding, Tommie W.

AU - Srkalovic, Gordan

AU - Schally, Andrew V

PY - 1989/12/1

Y1 - 1989/12/1

N2 - BDF female mice inoculated with MXT mammary adenocarcinoma were treated for 30 days with microcapsules of the luteinizing hormone-releasing hormone (LH-RH) agonist D-Trp-6-LH-RH (releasing 25 μg/day for 30 days), microcapsules of the somatostatin agonist RC-160 (liberating 25 μg/day for one month), or the combination of these peptides. Bilateral surgical ovariectomy was performed in one group which served as an additional control. Tumor volume was measured weekly during the treatment period of 30 days. When tumor volume changes in the treated groups were compared to the corresponding changes in controls, the combination of D-Trp-6-LH-RH and RC-160 was the most effective in inhibiting tumor growth and approached the effect of surgical ovariectomy. At the conclusion of the experiment, tumor weights were also measured. All peptide analogs inhibited tumor weight by 42 to 63%. In the D-Trp-6-LH-RH treated group, ovarian weights and uterine weights decreased by 48% and 52%, respectively, as compared to controls. Histologically, the regressive changes in tumors caused by the treatment with RC-160, D-Trp-6-LH-RH and their combination were characterized by the coexistence of apoptosis (programmed cell death) and coagulation necrosis. The transition of apoptosis into coagulation necrosis was a common finding. The term 'apoptotic index' is proposed for the ratio of tumorous glands containing apoptotic cells. The apoptotic index was higher in the treated groups than in the control.

AB - BDF female mice inoculated with MXT mammary adenocarcinoma were treated for 30 days with microcapsules of the luteinizing hormone-releasing hormone (LH-RH) agonist D-Trp-6-LH-RH (releasing 25 μg/day for 30 days), microcapsules of the somatostatin agonist RC-160 (liberating 25 μg/day for one month), or the combination of these peptides. Bilateral surgical ovariectomy was performed in one group which served as an additional control. Tumor volume was measured weekly during the treatment period of 30 days. When tumor volume changes in the treated groups were compared to the corresponding changes in controls, the combination of D-Trp-6-LH-RH and RC-160 was the most effective in inhibiting tumor growth and approached the effect of surgical ovariectomy. At the conclusion of the experiment, tumor weights were also measured. All peptide analogs inhibited tumor weight by 42 to 63%. In the D-Trp-6-LH-RH treated group, ovarian weights and uterine weights decreased by 48% and 52%, respectively, as compared to controls. Histologically, the regressive changes in tumors caused by the treatment with RC-160, D-Trp-6-LH-RH and their combination were characterized by the coexistence of apoptosis (programmed cell death) and coagulation necrosis. The transition of apoptosis into coagulation necrosis was a common finding. The term 'apoptotic index' is proposed for the ratio of tumorous glands containing apoptotic cells. The apoptotic index was higher in the treated groups than in the control.

KW - apoptosis

KW - D-Trp-6-LH-RH

KW - luteinizing hormone-releasing hormone (LH-RH)

KW - MXT mammary tumor

KW - programmed cell death

KW - somatostatin analog RC-160

UR - http://www.scopus.com/inward/record.url?scp=0024830886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024830886&partnerID=8YFLogxK

U2 - 10.1007/BF01806302

DO - 10.1007/BF01806302

M3 - Article

C2 - 2575407

AN - SCOPUS:0024830886

VL - 14

SP - 307

EP - 314

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -